Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Remission of severe CD8(+) cytotoxic T cell skin infiltrative disease in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy.

Sbidian E, Battistella M, Rivet J, Flageul B, Molina JM, Joly P, Caumes E, Gorochov G, Cayuela JM, Rabian C, Dupin N, Lebbé C, Janin A, Janier M, Oksenhendler E, Bachelez H.

Clin Infect Dis. 2010 Sep 15;51(6):741-8. doi: 10.1086/655895.

PMID:
20687841
2.

Human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy maintain activated CD8+ T cell subsets as a strong adaptive immune response to cytomegalovirus.

Villacres MC, Lacey SF, La Rosa C, Krishnan R, Auge C, Longmate J, Zaia JA, Leedom JM, Diamond DJ.

J Infect Dis. 2001 Aug 1;184(3):256-67. Epub 2001 Jul 10.

PMID:
11443550
3.

Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).

Gray CM, Lawrence J, Schapiro JM, Altman JD, Winters MA, Crompton M, Loi M, Kundu SK, Davis MM, Merigan TC.

J Immunol. 1999 Feb 1;162(3):1780-8.

4.

Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection.

Lascar RM, Lopes AR, Gilson RJ, Dunn C, Johnstone R, Copas A, Reignat S, Webster G, Bertoletti A, Maini MK.

J Infect Dis. 2005 Apr 1;191(7):1169-79. Epub 2005 Feb 28.

PMID:
15747254
5.

Human immunodeficiency virus type I-specific CD8+ T cell subset abnormalities in chronic infection persist through effective antiretroviral therapy.

Pohling J, Zipperlen K, Hollett NA, Gallant ME, Grant MD.

BMC Infect Dis. 2010 May 25;10:129. doi: 10.1186/1471-2334-10-129.

7.
9.
11.
12.

Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy.

Fraunholz I, Weiss C, Eberlein K, Haberl A, Rödel C.

Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1425-32. doi: 10.1016/j.ijrobp.2009.03.060. Epub 2009 Sep 8.

PMID:
19744801
13.

Influence of antiretroviral therapy on programmed death-1 (CD279) expression on T cells in lymph nodes of human immunodeficiency virus-infected individuals.

Ehrhard S, Wernli M, Dürmüller U, Battegay M, Gudat F, Erb P.

Hum Pathol. 2009 Oct;40(10):1427-33. doi: 10.1016/j.humpath.2008.11.019. Epub 2009 May 12.

PMID:
19439344
14.

CD8 T-cell response to antiretroviral therapy.

Stricker RB, Goldberg B.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Jun 1;15(2):176-7. No abstract available.

PMID:
9241121
15.

Control of human cytomegalovirus infection in patients infected with human immunodeficiency virus by high levels of specific CD8+ T-cells.

Lilleri D, Chiesa A, Fornara C, Maserati R, Lozza L, Comolli G, Gerna G.

Clin Microbiol Infect. 2007 Jan;13(1):19-24.

16.

Immunologic profile of human immunodeficiency virus-infected patients during viral remission and relapse on antiretroviral therapy.

Wellons MF, Ottinger JS, Weinhold KJ, Gryszowka V, Sanders LL, Edwards LJ, Gooding ME, Thomasch JR, Bartlett JA.

J Infect Dis. 2001 May 15;183(10):1522-5. Epub 2001 Apr 17.

PMID:
11319689
17.

[Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].

Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.

Zhonghua Yi Xue Za Zhi. 2007 Nov 13;87(42):2973-6. Chinese.

PMID:
18261327
18.

Alterations in T cell phenotype and human immunodeficiency virus type 1-specific cytotoxicity after potent antiretroviral therapy.

Seth A, Markee J, Hoering A, Sevin A, Sabath DE, Schmitz JE, Kuroda MJ, Lifton MA, Hirsch MS, Collier AC, Letvin NL, McElrath MJ.

J Infect Dis. 2001 Mar 1;183(5):722-9. Epub 2001 Feb 1.

PMID:
11181148
19.

Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells.

Kostense S, Otto SA, Knol GJ, Manting EH, Nanlohy NM, Jansen C, Lange JM, van Oers MH, Miedema F, van Baarle D.

Eur J Immunol. 2002 Apr;32(4):1080-9.

20.

A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals.

Larsson M, Jin X, Ramratnam B, Ogg GS, Engelmayer J, Demoitie MA, McMichael AJ, Cox WI, Steinman RM, Nixon D, Bhardwaj N.

AIDS. 1999 May 7;13(7):767-77.

PMID:
10357375

Supplemental Content

Support Center